Clinical Trials - May 6, 2026
Spago Nanomedical reports phase I/IIa study data
The independent Data Monitoring Committee (DMC) of the Tumorad-01 study declared that a primary endpoint, identifying the maximum tolerated dose, has been met and recommends that an additional two patients are enrolled at the dose level of 15 MBq/kg to provide a basis for defining a recommended phase II dose and completion of the phase I part of the study.
Clinical Trials Medtech - October 1, 2024
Elekta presents promising initial results from the UNITED trial
Jay Detsky, radiation oncologist at Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada, has presented initial cancer control outcomes from the UNITED trial (Unity-Based MR-Linac Guided Adaptive Radiotherapy for High Grade Glioma).
Clinical Trials Medtech - January 16, 2024
OssDsign reports new clinical study data
OssDsign has announced that positive data from the clinical study TOP FUSION has been submitted to a peer-reviewed scientific journal. Top-line results show a 93 % spinal fusion rate at 12 months as assessed with CT by independent radiological review from Medical Metrics Inc. after surgery with the novel nanosynthetic bone graft OssDsign Catalyst, states […]
Clinical Trials - October 23, 2023
Spago Nanomedical to initiate phase I/IIa study in Australia
The company’s application to start the clinical phase I/IIa study, Tumorad-01, with the candidate drug 177Lu-SN201 in cancer patients has been approved. The first patient is expected to be included shortly, states the company. “We are very excited and strongly motivated to now start the first clinical study with Tumorad. The study is designed in […]
Clinical Trials - May 2, 2022
AI Medical Technology initiates clinical study
AI Medical Technologies announces the start of a clinical trial at 30 Swedish primary care facilities with Dermalyser, a diagnostic decision support system empowered with advanced artificial intelligence (AI). The study is a prospective, confirmatory multi-centre, non-interventional clinical investigation with the aim to evaluate the clinical safety, performance and benefit of Dermalyser in patients with […]
Clinical Trials Medtech - March 16, 2022
Otivio extends exploratory clinical trial
The Norwegian healthtech company Otivio has extended an exploratory clinical trial with Neuro-SysMed to confirm the potential of its FlowOx medical device to alleviate multiple sclerosis symptoms. The trial follows a recent case series of 7 people with MS (pwMS) conducted by neurologist Dr Gabriela Fortes where FlowOx significantly alleviated MS related spasticity and pain, […]
